TNFRSF8 and classic Hodgkin lymphoma: These favorable results were confirmed in a phase II study on 15 multi-refractory cHL patients in which anti-CD30 CAR T-cell infusion resulted in an ORR of 73.3% with a CR rate of 60% and very low rates of acute toxicities.